"To dream may not be rational, but you must dream" - @CEO_TEVOGEN_BIO $TVGN

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/xaz8O0rDqr Mittul Mehta will share perspectives on https://t.co/ASvpTnkuvh’s application of advanced data and AI technologies, including its PredicTcell™ platform, developed in collaboration with Microsoft and Databricks, to accelerate

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/2kvTvuYEU6 Risk adjusted Net Present Value for TVGN 116 is estimated to exceed ~$325 million in the US alone. $TVGN #affordable #accessible #celltherapy #Oncology #LiverCancer #HepatitisB

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/CVxvyGHY7q “Two cancer patients were able to proceed to stem cell transplant just 15 and 28 days after receiving TVGN-489, a procedure that effectively eliminates the patient’s immune system and requires months for recovery. Remarkably,

We anticipate releasing internal valuations of most assets by mid-next week. Stay tuned. $TVGN #Assets https://t.co/tIAJWRC8CQ

$TVGN #Assets #CellularTherapy #AIinMedicine #Growth

“The XFG variant of #SARSCoV2 surging now, is a reminder that COVID-19 is not limited to just the winter months and remains a threat to those with weakened immune systems," said Dr. Neal Flomenberg, Chief Science Officer at Tevogen. “Surveillance of this virus and treatment for

“An intact immune system is necessary to cure viral infections and TVGN 489 is designed to directly provide this immune help to individuals who need it.” - Ryan Saadi, @TevogenBio @CEO_TEVOGEN_BIO @TevogenAI $TVGN @Nasdaq #COVID_19 #Longcovid #celltherapy https://t.co/h4PLIfFlkv

📰 https://t.co/CTRUmzcc75 “Contributions like this help ensure the ongoing success of Opportunity Project and our innovative Clubhouse program while guaranteeing that no individual with a brain injury is ever turned away due to an inability to pay,” said Kerri Berson Levine,

📰 https://t.co/CTRUmzcc75 “Contributions like this help ensure the ongoing success of Opportunity Project and our innovative Clubhouse program while guaranteeing that no individual with a brain injury is ever turned away due to an inability to pay,” said Kerri Berson Levine,

👋 𝐓𝐞𝐚𝐦 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 👋 𝐌𝐞𝐞𝐭 𝐃𝐚𝐯𝐢𝐝 𝐁𝐚𝐧𝐤𝐨! Speaking to reimbursement planning he commented: "Integrating comprehensive market access strategies with clinical product development facilitates proactive timely communication to all stakeholders - physicians,

👋 𝐓𝐞𝐚𝐦 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 👋 𝐌𝐞𝐞𝐭 𝐀𝐥𝐥𝐲𝐬𝐨𝐧 𝐎'𝐂𝐨𝐧𝐧𝐨𝐫! Speaking to inhouse manufacturing she commented, "With a background in biotech and clinical manufacturing, I understand the impact that in-house manufacturing capabilities have on both product quality and

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/1GweoRrds7 "The accounting treatment of internally developed assets may not fully capture their value, but our wholly owned intellectual property, proprietary platforms, advanced AI technologies, strategic partnerships, discovery lab,

👋 𝐓𝐞𝐚𝐦 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 👋 Tevogen’s leadership brings 300+ years of combined expertise across drug development, commercialization, investment banking, and AI in healthcare. $TVGN #affordable #accessible #celltherapy #leadership

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/AVghb3xUBP “We are humbled and honored by this recognition,” said Dr. Saadi. “As Yale has highlighted, affordability and accessibility are not just aspirational goals for Tevogen, they are the foundation of how we operate. We’ve

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://t.co/eQo9AK2h6h As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased 24% compared to the reported amount on March 31, 2025; this is following a 60% increase reported for the first quarter.